Finoriq research workspace
Zura Bio Ltd (ZURA) SEC Filings & Filing Highlights
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune. Review ZURA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
- Company
- Zura Bio Ltd (ZURA)
- Ticker
- ZURA
- Market Cap
- $501.6M
- Latest Price
- $5.28
- Industry
- Biotech & Pharma
Zura Bio Ltd (ZURA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Zura Bio Ltd (ZURA).
| Event | Form | Date |
|---|---|---|
| Corporate Overview July 2026 Nasdaq Ticker: ZURACorporate Overview July 2026 Nasdaq Ticker: ZURA | 8-K7.01 | 2026-07-01 |
| As referenced above, on June 17, 2026, the Company held its Annual Meeting, at which a quorum w...As referenced above, on June 17, 2026, the Company held its Annual Meeting, at which a quorum was present. At the Annual Meeting, the share... | 8-K5.07 | 2026-06-18 |
| On June 17, 2026, Zura Bio Limited (the “Company”) held its Annual General Meeting of Sharehold...On June 17, 2026, Zura Bio Limited (the “Company”) held its Annual General Meeting of Shareholders (the “Annual Meeting”), at which a quoru... | 8-K5.02 | 2026-06-18 |
| Director Resignation On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of...Director Resignation On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of di... | 8-K5.02 | 2026-05-22 |
| Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates | 8-K7.01 | 2026-05-07 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.